Plasma membrane cholesterol controls the cytotoxicity of Alzheimer's disease AbetaP (1-40) and (1-42) peptides.
Cell degeneration in Alzheimer's disease is mediated by a toxic mechanism that involves interaction of the AbetaP peptide with the plasma membrane of the target cell. We report here that PC12 cells become resistant to the cytotoxic action of AbetaP when incubated in a medium that enriches cholesterol levels of the surface membrane. On the other hand, making cholesterol-deficient membranes by either cholesterol extraction with cyclodextrin or by inhibiting de novo synthesis of cholesterol makes PC12 cells more vulnerable to the action of AbetaP. Increasing cholesterol content of PS liposomes also suppresses AbetaP-dependent liposome aggregation. We suggest that by modifying the fluidity of the neuronal membranes, cholesterol modulates the incorporation and pore formation of AbetaP into cell membranes. This idea is supported by our finding that the enhanced cytotoxicity generated by lowering the membrane cholesterol content can be reversed by AbetaP calcium channel blockers Zn2+ and tromethamine.
Arispe
Nelson
N
Department of Anatomy, Physiology and Genetics, and Institute for Molecular Medicine, Uniformed Services University School of Medicine, USUHS, Bethesda, Maryland 20814, USA. narispe@usuhs.mil
Doh
Michael
M
D016229:Amyloid beta-Peptides / Q000494:pharmacology*; D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology; D002462:Cell Membrane / Q000378:metabolism*; D002470:Cell Survival / Q000187:drug effects*; D002784:Cholesterol / Q000378:metabolism / Q000494:pharmacology*; D003505:Cyclodextrins / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D008081:Liposomes / Q000378:metabolism / Q000494:pharmacology; D008148:Lovastatin / Q000031:analogs & derivatives* / Q000494:pharmacology; D016716:PC12 Cells; D010446:Peptide Fragments / Q000494:pharmacology*; D010718:Phosphatidylserines / Q000378:metabolism / Q000494:pharmacology; D051381:Rats; D014325:Tromethamine / Q000494:pharmacology; D015032:Zinc / Q000494:pharmacology; D047392:beta-Cyclodextrins
D016229:Amyloid beta-Peptides; D000924:Anticholesteremic Agents; D003505:Cyclodextrins; D008081:Liposomes; D010446:Peptide Fragments; D010718:Phosphatidylserines; C078592:amyloid beta-protein (1-40); C075222:amyloid beta-protein (1-42); D047392:beta-Cyclodextrins; C108732:methyl-beta-cyclodextrin; D014325:Tromethamine; C012258:mevastatin; D002784:Cholesterol; D008148:Lovastatin; D015032:Zinc